{"id":"NCT00621140","sponsor":"Boehringer Ingelheim","briefTitle":"Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control","officialTitle":"A Randomised, Double-blind, Placebo-controled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug Naive or Previously Treated (6 Weeks Washout) Type 2 Diabetic Patients With Insufficient Glycemic Control","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02","primaryCompletion":"2009-05","completion":null,"firstPosted":"2008-02-22","resultsPosted":"2011-06-07","lastUpdate":"2014-02-17"},"enrollment":503,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"linagliptin","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"linagliptin 5 mg","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To investigate efficacy, safety and tolerability of BI 1356 versus placebo","primaryOutcome":{"measure":"HbA1c Change From Baseline at Week 24","timeFrame":"Baseline and week 24","effectByArm":[{"arm":"Placebo","deltaMin":0.25,"sd":0.07},{"arm":"Linagliptin","deltaMin":-0.44,"sd":0.05}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":69,"countries":["Croatia","India","Israel","Italy","Malaysia","Netherlands","Poland","Romania","Slovakia","Thailand","Ukraine"]},"refs":{"pmids":["27484756","22234149"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":167},"commonTop":["Hyperglycaemia"]}}